Skip to main navigation

Main Corporate Nav

  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Partnering
    • Our History
  • Pipeline
    • Overview
    • AL Amyloidosis & Birtamimab
    • Parkinson's Disease & Prasinezumab
    • ATTR Amyloidosis & PRX004
    • Alzheimer's Disease
    • Pioneering Neuroscience
    • Publications
  • Clinical Trials
    • Overview
    • Birtamimab Phase 3 Study
    • Prasinezumab Phase 2 Study
    • PRX004 Phase 1 Study
    • Expanded Acces Policy
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financial & Filings
    • Corporate Governance
    • Stock information
    • Analyst Coverage
  • Careers
    • Overview
    • Our Values
    • Compensation & Benefits
    • Opportunities
    • Public House
  • Contact Us
    About Us
    • Leadership
    • Board of Directors
    • Partnering
    • Our History
    • About Us
      • Management
      • Board of Directors
      • Partnering
      • Our History
    • Pipeline
      • Parkinson’s Disease & prasinezumab
      • ATTR Amyloidosis & PRX004
      • Alzheimer’s Disease
      • Neuroscience Discovery Programs
      • Publications
    • Clinical Trials
      • Prasinezumab Phase 2 Study
      • PRX004 Phase 1 Study
      • Expanded Access Policy
    • Investors
      • Press Releases
      • Events & Presentations
      • Financials & Filings
      • Corporate Governance
      • Stock Information
      • Analyst Coverage
    • Careers
      • Our Values
      • Compensation & Benefits
      • Opportunities
      • Public House
    • Contact Us
    • Menu Menu

    Stock Information

    Investor Relations

    • Overview
    • Press Releases
    • Events & Presentations
    • Financials & Filings
      • SEC Filings
      • Quarterly Results
      • Key Ratios
      • Irish Statutory Financial Statements
    • Corporate Governance
      • Committee Composition
    • Stock Information
    • Analyst Coverage

    Shareholder Tools

    Stock Information

    Stock Quote

    Change
    Volume
    Today's Open
    Previous Close
    Today's High
    Today's Low
    52 Week High
    52 Week Low

    Stock Chart

    Data Provided by Refinitiv. Minimum 15 minutes delayed.

    Main Corporate Nav

    • About Us
      • Overview
      • Leadership
      • Board of Directors
      • Partnering
      • Our History
    • Pipeline
      • Overview
      • AL Amyloidosis & Birtamimab
      • Parkinson's Disease & Prasinezumab
      • ATTR Amyloidosis & PRX004
      • Alzheimer's Disease
      • Pioneering Neuroscience
      • Publications
    • Clinical Trials
      • Overview
      • Birtamimab Phase 3 Study
      • Prasinezumab Phase 2 Study
      • PRX004 Phase 1 Study
      • Expanded Acces Policy
    • Investors
      • Overview
      • Press Releases
      • Events & Presentations
      • Financial & Filings
      • Corporate Governance
      • Stock information
      • Analyst Coverage
    • Careers
      • Overview
      • Our Values
      • Compensation & Benefits
      • Opportunities
      • Public House
    • Contact Us

    2021© Prothena | Terms of Use | Privacy Policy

    Scroll to top